Introduction: Paclitaxel is a microtubule stabilizer that is currently one of the most utilized
chemotherapeutic agents. Its efficacy in breast, uterine, lung and other neoplasms made its …

The causes of variation in toxicity to the same treatment regimen among seemingly similar
patients remain largely unknown. There was tremendous optimism that the patient's …

Chemotherapy induced peripheral neuropathy (CIPN) is an often severe and debilitating
complication of multiple chemotherapeutic agents that can affect patients of all ages, across …

Background: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common
complication of cancer treatment that produces functional disability. Increasingly, patient …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting toxicity
that affects 30%–40% of patients undergoing cancer treatment. Although multiple …

Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer.
Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most …

Polygenic models have emerged as promising prediction tools for the prediction of complex
traits. Currently, the majority of polygenic models are developed in the context of predicting …

Resistance to anti-cancer drugs is the main challenge in oncology. In pre-clinical studies,
established cancer cell lines are primary tools in deciphering molecular mechanisms of this …

Pharmacogenetics (PGx) seeks to enable selection of the right dose of the right drug for
each patient to optimize therapeutic outcomes. Most PGx focuses on pharmacokinetics …

Introduction: Peripheral neuropathy (PN) is an adverse effect of several classes of
chemotherapy including the taxanes. Predictive PN biomarkers could inform individualized …